NCT07540260 CAIX PET/ CT Guided Radiation Therapy in CcRCC.
| NCT ID | NCT07540260 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University First Hospital |
| Condition | Radiation Therapy |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2025-11-01 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2025-11-01 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, single-arm study in adults with recurrent or metastatic clear cell renal cell carcinoma (ccRCC). Participants will receive standard systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) and undergo dual PET/CT imaging (FDG PET/CT and a CAIX-targeted PET/CT) to map disease sites. When feasible, PET/CT-visible lesions will be treated with image-guided stereotactic ablative radiotherapy (SABR). Patients will be followed to evaluate progression-free survival, local control of treated lesions, and treatment-related adverse events (planned enrollment: \~70).
Eligibility Criteria
Inclusion Criteria: Adults (≥18 years) Histologically confirmed clear cell renal cell carcinoma Recurrent or metastatic disease Planned or ongoing first-line systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) Dual PET/CT imaging available (FDG PET/CT and CAIX-targeted PET/CT) and eligible for radiotherapy planning Multidisciplinary assessment confirms radiotherapy is feasible to treat ≥75% of detectable lesions Able to provide written informed consent Exclusion Criteria: Unable to receive stereotactic radiotherapy as planned Uncontrolled serious comorbidities or active infection Pregnant or breastfeeding Unable or unwilling to comply with study procedures and follow-up
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07540260 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Radiation Therapy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07540260 currently recruiting?
Yes, NCT07540260 is actively recruiting participants. Contact the research team at drmingweima@bjmu.edu.cn for enrollment information.
Where is the NCT07540260 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07540260 clinical trial?
NCT07540260 is sponsored by Peking University First Hospital. The trial plans to enroll 70 participants.